Microarray analysis following Anti-Inflammatory Interventions in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

• Conditions: Chronic Obstructive Pulmonary Disease; Ex-smokers with obstructive airway disease; Respiratory - Chronic obstructive pulmonary disease

• Registration Number: ACTRN12611000165987
• Lead Sponsor: Hunter New England Health Service

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-02-11
• Study Completion: 2012-12-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

Ex-smokers with a smoking history of a least 10 pack years, obstructive airway disease (FEV1/FVC ratio < 2SD below expected value for age, sex and height)

Exclusion Criteria

Currently taking lipid lowering drugs or drugs that interact with statins, Subjects with active liver disease, renal impairment, cardiovascular disease, pregnant or breast feeding, subjects with known allergies or intolerance to statins or one of the dietary supplements

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
sing microarray analysis, sputum mRNA expression data[0, 4 and 12 weeks]

Secondary Outcome Measures

Name	Time	Method
il[Nil]